Key result
Transcatheter aortic valve-in-valve implantation for failing bioprostheses showed similar 30-day mortality to redo surgical replacement, despite a higher patient risk profile.
Why the study?
Does transcatheter aortic valve-in-valve implantation improve outcomes compared to redo surgical aortic valve replacement in patients with failed aortic bioprostheses?
Cohort (n=130)
Yes
Does transcatheter aortic valve-in-valve implantation improve outcomes compared to redo surgical aortic valve replacement in patients with failed aortic bioprostheses?
Answers are grounded in this paper and cite their sources.
Transcatheter valve-in-valve implantation offers similar early mortality to redo surgical aortic valve replacement in patients with failed bioprostheses, despite higher baseline surgical risk, though it is associated with higher transvalvular gradients.
OBJECTIVES: Transcatheter aortic valve-in-valve implantation (ViV) is a new treatment for failing bioprostheses (BP) in patients with high surgical risk. However, comparative data, using standard repeat surgical aortic valve replacement (redo-SAVR), are scarce. We compared outcomes after ViV with those after conventional redo-SAVR in two European centres with established interventional programmes. METHODS: In-hospital databases were retrospectively screened for patients ≥60 years, treated for failing aortic BP. Cases of infective endocarditis or combined procedures were excluded. End-points were adjudicated according to the Valve Academic Research Consortium (VARC-2) criteria. RESULTS: From 2002 to 2015, 130 patients were treated (ViV: n = 71, redo-SAVR: n = 59). Age and logistic EuroSCORE I scores were higher with ViV (78.6 ± 7.5 vs 72.9 ± 6.6 years, P < 0.01; 25.1 ± 18.9 vs 16.8 ± 9.3%, P < 0.01). The 30-day mortality rate was not significantly different (4.2 and 5.1%, respectively) (P = 1.0). Device success was achieved in 52.1% (ViV) and 91.5% (P < 0.01). No stroke was observed after ViV but in 3.4% after redo-SAVR (P = 0.2). Intensive care stay was longer after redo-SAVR (3.4 ± 2.9 vs 2.0 ± 1.8 days, P < 0.01). Mean transvalvular gradients were higher post-ViV (19.7 ± 7.7 vs12.2 ± 5.7 mmHg, P < 0.01), whereas the rate of permanent pacemaker implantation was lower (9.9 vs 25.4%, P < 0.01). Survival rates at 90 and180 days were 94.2 and 92.3% vs 92.8 and 92.8% (P = 0.87), respectively. CONCLUSIONS: Despite a higher risk profile in the ViV group, early mortality rates were not different compared with those of surgery. Although ViV resulted in elevated transvalvular gradients and therefore a lower rate of device success, mortality rates were similar to those with redo-SAVR. At present, both techniques serve as complementary approaches, and allow individualized patient care with excellent outcomes.
No takes yet. Share an insight, caveat, or question.
Silaschi et al. (2016) conducted a cohort in Failing aortic bioprostheses (n=130). Transcatheter aortic valve-in-valve implantation (ViV) vs. Redo surgical aortic valve replacement (redo-SAVR) was evaluated on 30-day mortality (p=1.0). Transcatheter aortic valve-in-valve implantation for failing bioprostheses showed similar 30-day mortality to redo surgical replacement, despite a higher patient risk profile.
Synapse has enriched 10 related papers. Consider them for comparative context: